Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia

M. Hoover, Elaine R Morgan, Morris Kletzel*

*Corresponding author for this work

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.

Original languageEnglish (US)
Pages (from-to)268-273
Number of pages6
JournalMedical and Pediatric Oncology
Volume28
Issue number4
DOIs
StatePublished - Apr 1 1997

Fingerprint

Mycoses
Leukemia
Bone Marrow
Transplants
Bone Marrow Transplantation
Amphotericin B
Mucormycosis
Lung
Chemoprevention
Infection Control
Fungi
Spleen

Keywords

  • antifungal treatment modalities
  • surgical resection
  • systemic amphotericin B

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

@article{4634691823aa49bcac77f101756703af,
title = "Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia",
abstract = "Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.",
keywords = "antifungal treatment modalities, surgical resection, systemic amphotericin B",
author = "M. Hoover and Morgan, {Elaine R} and Morris Kletzel",
year = "1997",
month = "4",
day = "1",
doi = "10.1002/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G",
language = "English (US)",
volume = "28",
pages = "268--273",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Prior fungal infection is not a contraindication to bone marrow transplant in patients with acute leukemia

AU - Hoover, M.

AU - Morgan, Elaine R

AU - Kletzel, Morris

PY - 1997/4/1

Y1 - 1997/4/1

N2 - Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.

AB - Purpose: Our aim was to assess the feasibility of bone marrow transplantation (BMT) in patients with acute leukemia who have had prior documented invasive fungal infection within 5 months pretransplant treated aggressively with systemic amphotericin B and, when applicable, surgical resection of the infected tissue. Materials and Methods: We reviewed the charts of patients with acute leukemia at our institution who underwent BMT between August 1992 and April 1994 after being treated for a severe fungal infection. We evaluated criteria for diagnosis of fungal infection, timing of infection in relation to BMT, and antifungal treatment modalities. We determined peritransplant complications, evidence for recurrence of fungal infection during BMT, morbidity related to antifungal drug therapy, and overall outcome in each patient. Results: Fungal infection developed in eight patients. Sites of involvement included lung, liver, spleen, and skin. All patients were treated with systemic amphotericin B. Some also underwent surgical resection of infected tissue following clinical control of infection. All patients underwent BMT. Seven of eight patients engrafted and survived BMT. One patient died of recurrent pulmonary mucormycosis. Three patients are alive and free of leukemia and fungal disease. Four patients died of noninfectious causes and had no evidence of fungal disease at the time of death. Conclusions: Aggressive therapy of prior fungal infection followed by ongoing anti-fungal prophylaxis in acute leukemia patients may allow BMT without reactivation of the fungus. Reports of larger series of such patients as well as studies of the efficacy of chemoprophylaxis of fungal infections are needed.

KW - antifungal treatment modalities

KW - surgical resection

KW - systemic amphotericin B

UR - http://www.scopus.com/inward/record.url?scp=0030908943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030908943&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G

DO - 10.1002/(SICI)1096-911X(199704)28:4<268::AID-MPO5>3.0.CO;2-G

M3 - Article

C2 - 9078323

AN - SCOPUS:0030908943

VL - 28

SP - 268

EP - 273

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -